What Фарматекс Treats: Main Uses and Benefits

The product's therapeutic area focuses on Local Contraception (pregnancy prophylaxis), which serves as its primary area of use.

Contraceptive Support for Episodic Protection

This medication is used in the therapeutic domain of reproductive health to help manage the risk of unintended conception. It is applied in addressing conditions involving episodic or fluctuating manifestations, and is commonly used when short-term symptomatic assistance is needed. The core clinical scenarios covered include: situational contraception, adjunct use with other barrier methods, and use when systemic methods are paused. This may assist with family planning goals and supports reproductive timing through situational risk management.

“This therapeutic option helps address the need for a method independent of systemic hormonal processes.”

Non-Systemic Option for Hormone-Free Management

Фарматекс provides a relevant therapeutic option for patient groups who require pregnancy prophylaxis without systemic hormonal intervention. This use is important for breastfeeding women, post-partum patients, and individuals who prefer not to use systemic hormonal methods. This therapeutic benefit allows patients to pursue birth control while preserving their body's natural hormonal balance and may assist with maintaining functional stability related to the menstrual cycle or lactation.

Quick Fact: Support for Reproductive Health
Supports non-systemic management of conception risk.

The eligibility for using Фарматекс (Benzalkonium Chloride) is defined by official regulatory documents based on the user's health status, reproductive state, and adherence to specific usage constraints.

Regulatory Eligibility Classifications

Classification	Population/Condition
Contraindicated	Known hypersensitivity or allergy to benzalkonium chloride or any excipient.
Generally Permitted	All women of reproductive age, including postpartum and pre-menopausal women.
Conditional Use	Use must cease if a genital lesion develops or worsens.
Not Recommended	Individuals who cannot comply with the strict instructions for use.

Eligibility Status by Physiological State

• Pregnancy: If used accidentally at the beginning of an unknown pregnancy, regulatory data indicate it is not contra-indicated due to minimal systemic absorption.
• Lactation (Breastfeeding): Use is officially not contra-indicated and is classified as possible, as the active substance does not diffuse into the blood or breast milk.

Eligibility-Related Restriction: The medicine is inactivated by soap and other anionic surfactants; therefore, use is restricted to individuals who will avoid washing the genital area with soap or using other vaginal treatments around the time of use.

The official regulatory profile for Фарматекс (Benzalkonium chloride) is characterized by highly specific local chemical incompatibilities rather than systemic drug-drug interactions. No systemic pharmacokinetic interactions involving CYP enzymes or drug transporters are documented in the official labeling, consistent with the minimal systemic absorption of the active ingredient.

---

Prohibited Substances and Local Inactivation

Co-administration with specific substances is formally prohibited because they chemically destroy the spermicide. This includes soaps and other anionic surfactants, which are documented to inactivate the active ingredient, benzalkonium chloride, even in trace amounts.

The labeling also formally classifies medicinal products for vaginal administration as combinations that are not recommended. Any such local treatment is likely to interfere with and inactivate the local contraceptive action.

---

Timing and Activity Restrictions

Regulatory documents impose mandatory constraints on timing and activities to preserve efficacy:

• Washing with Soap: The washing of genitals with soap must be avoided for two hours before and two hours after intercourse.
• Vaginal Douching: If douching is desired, even with pure water, the user must wait for at least two hours after administration to avoid eliminating the product.
• Bathing or Swimming: Activities such as bathing or swimming (in a sea or pool) are documented to affect the product's efficacy and must be avoided, as the contraceptive action may be reduced.

Cationic Lysis: The Immediate Spermicidal Mechanism

The action of Фарматекс is purely physicochemical, centered on its active ingredient, benzalkonium chloride, which functions as a cationic surfactant. This molecule is drawn to the negative charge of the spermatozoal plasma membrane, resulting in its intercalation and subsequent rupture (lysis). This primary mechanism of structural destruction disrupts the sperm's physical integrity, resulting in the loss of structural containment.

Enzymatic Deactivation and Loss of Viability

Following membrane lysis, the chemical nature of the surfactant further acts by denaturing essential intracellular enzymes required for metabolism and motility. This cascade results in the loss of sperm viability and leads to irreversible immobilization of the sperm cells. Because the action is strictly localized within the vaginal cavity, this mechanism affects the sperm population without influencing systemic physiological pathways.

Mechanistic Limitations and Contact Dependence

The efficacy of this contact-dependent mechanism relies on the full dispersion of the active substance to encounter all viable sperm. Crucially, the cationic action of the drug is instantly neutralized by the presence of anionic surfactants found in common soaps and detergents, demonstrating a specific chemical limitation if the drug's interaction with anionic surfactants occurs.

Фарматекс (Benzalkonium chloride) is administered locally via the vaginal route using approved dosage forms, which include vaginal pessaries (typically 18.9 mg of the active ingredient) and vaginal cream. The product is strictly for local application and is not intended to be taken orally.

The core principle of use follows a situational dosing schedule based on the frequency of intercourse. One unit of the product, such as a single pessary, is required and applied systematically before each act of sexual intercourse, irrespective of the user's menstrual cycle period. If intercourse is repeated, or if the time window of protection from the initial dose expires, a new unit must be inserted to maintain the intended usage pattern.

Proper administration requires placing the unit high into the vagina. For forms like the pessary, a waiting period of approximately 5 minutes after insertion before intercourse is necessary to allow for sufficient dissolution and activation of the spermicide. A single pessary provides a time-limited duration of protection, typically 4 hours.

A key procedural constraint involves ensuring the integrity of the active substance. Since soap inactivates benzalkonium chloride, users must avoid washing the genitals with soap for 2 hours before and 2 hours after administration; only external washing with pure water is permitted. The product should not be used concurrently with other vaginally-administered medications. The use of Фарматекс is not applicable for children.

Research evidence / Overview of studies for Фарматекс

Evidence for Use in Local Contraception

Research was conducted for the indication of local contraception and pregnancy prophylaxis. Studies exploring this topic include multicentre prospective clinical trials and comparative randomized controlled trials (RCTs) that research examined across various geographical regions. Researchers primarily examined contraceptive incidence, which was studied for using the Pearl Index (PI)—a standard tool in reproductive health research—to describe the number of pregnancies observed in a specified time interval in the study population. These trials also tracked cumulative pregnancy rates during the observation periods.

Findings describe patterns observed in the studies related to the Pearl Index and show that the PI measurements differ based on perfect use versus typical use. Perfect use reflects systematic and correct application before every act of intercourse, while typical use accounts for real-world user adherence, which may fluctuate. The data show patterns related to the finding that efficacy outcomes may be sensitive to consistent user application.

Major regulatory and public health organizations generally note that the spermicide product class data are still emerging when compared to other available contraceptive methods, a point which further contributes to the broader evidence landscape.

Research on User Adherence and Acceptability

Beyond measurements of contraceptive incidence, studies explored patient-reported experiences related to the product. These trials monitored factors such as user acceptability, overall satisfaction, and adherence to the systematic application schedule.

The research reports patterns of acceptability among the women who participated in the studies. Findings help contextualize how patients reported their experience and indicated that most participants found the application and use acceptable. Studies monitored continuation rates to see how long women were likely to use the method, and these data show patterns related to the satisfaction and acceptability of non-systemic options.

Evidence in Specific Population Cohorts

The product was evaluated in specific subgroups of women. Notably, research has examined its use in the cohort of women aged 40 and over, a group was observed in research exploring how symptoms change over time compared to younger populations.

These specialized studies explored similar research methodologies, focusing on the Pearl Index measurement and cumulative pregnancy rates in this cohort. Studies help show what has been observed so far in this specific age group.

Intermediate-Term Studies and Follow-up

The observation periods in the key clinical trials research examined over defined time intervals. The typical mandatory study period was six months, with some trials including an optional extension up to 12 months.

Therefore, long-term effects are not fully established. There is limited information for long-term outcomes for women using the product continuously for periods exceeding one year.

What is Still Uncertain About the Research for Фарматекс

One of the main research limitation frames is the finding that efficacy may be sensitive to user adherence; data show patterns related to how inconsistent use was associated with different measurements.

Furthermore, while findings exist for the group of women aged 40 and over, the subgroup findings are uncertain. Researchers noted that results from this age cohort was observed in some studies and may require independent confirmation through additional, targeted research. Comparative evidence against other non-hormonal options is lacking in some areas. Overall, the studies contribute to the broader evidence landscape. Research provides context but not individual predictions, as study results reflect the specific conditions under which they were conducted.

Key Studies & References

1. Effectiveness of BenZalKonium chloride gel as vaginal contraceptive: a multicentric randomised controlled trial (ISRCTN Registry)

Common questions about Фарматекс (FAQ)

Q: What is the main purpose of Фарматекс?

Фарматекс (also known by its active ingredient, benzalkonium chloride) is a spermicidal contraceptive used to prevent pregnancy. It works by damaging the cell membrane of sperm, which immobilizes and destroys them before they can reach the egg. It must be used correctly with every sexual encounter to be effective.

---

Q: How is Фарматекс typically used or applied?

Фарматекс is available in several forms, including vaginal cream, ovules (suppositories), and tampons. The specific directions depend on the form:

• Cream: A dose is inserted deep into the vagina before intercourse. The protection is immediate.
• Ovules/Suppositories: An ovule is inserted deep into the vagina and must fully dissolve before intercourse. This usually takes 5 to 10 minutes.
• Tampons: A tampon is inserted and provides immediate protection.

A new application is required for every act of intercourse. Users must wait the required time for activation (if applicable) and also observe the minimum duration of effect to ensure coverage.

---

Q: Is Фарматекс effective at preventing sexually transmitted infections (STIs)?

No. Фарматекс is a contraceptive product designed only to prevent pregnancy. It does not protect against sexually transmitted infections (STIs), including HIV/AIDS. For protection against STIs, barrier methods, such as condoms, are necessary.

---

Q: How long does the contraceptive effect of Фарматекс last after application?

The duration of effectiveness varies slightly by the formulation:

• Cream: The contraceptive effect lasts for 10 hours after insertion.
• Ovules/Suppositories: The contraceptive effect lasts for 4 hours after the ovule has fully dissolved (approximately 5-10 minutes after insertion).
• Tampons: The contraceptive effect lasts for 4 hours after insertion.

Important: If the duration of effect is exceeded, or if another act of intercourse occurs, a new application is required.

---

Q: What should I do if I forget to use Фарматекс before intercourse?

If Фарматекс was not used correctly before or during intercourse, the contraceptive efficacy is compromised, and there is a risk of pregnancy. The product is not designed for post-coital (after sex) use. In this situation, the patient should speak with a healthcare provider immediately about emergency contraception options and testing for sexually transmitted infections (STIs).

---

Q: Can Фарматекс be used while bathing, swimming, or douching?

Water, soap, and other products can inactivate the active ingredient in Фарматекс. To maintain its effectiveness:

• Wait at least 2 hours after intercourse before washing the genital area with soap or taking a bath/shower.
• Do not use soap on the genital area for 2 hours before or after using Фарматекс.
• Do not douche (wash out the vagina) for several hours after intercourse, as this will wash away the active ingredient and compromise protection.

Only a gentle rinse with plain water is permitted immediately before and after use.

The storage and disposal instructions for Фарматекс are officially documented to maintain the product's quality and ensure environmental safety.

Official Storage Requirements

The medicine must be stored at a temperature not exceeding +25 C and kept out of the sight and reach of children. It should remain in its original container and be protected from environmental factors like excessive heat. If the ovules (pessaries) are exposed to heat and melt, regulatory labeling advises placing them in a fridge or under cold water for recovery without product alteration. For the cream formulation, regulatory guidance specifies a limited shelf-life of 3 months once the container is opened.

Official Disposal Instructions

Expired or unused portions of the medicine must not be thrown away via wastewater or household waste. This environmental restriction is necessary due to the nature of the active ingredient. Disposal must be carried out in accordance with local regulatory requirements for pharmaceutical waste, often requiring return to a pharmacy or an approved waste disposal plant.